Universal Vision Biotechnology Co

Universal Vision Biotechnology Co EBITDA per Share

The EBITDA per Share of Universal Vision Biotechnology Co (3218.TWO) as of Oct 27, 2026 is 16.25 TWD. In the previous year, EBITDA per Share was 16.55 TWD — a change of -1.80% (lower).

EBITDA per Share

16.25TWD

YoY

-1.80%

Last updated:

EBITDA per Share of Universal Vision Biotechnology Co is 2025 16.25 TWD. EBITDA per Share of Universal Vision Biotechnology Co was 2024 16.55 TWD. It decreases by -1.80% lower compared to the previous year.

The Universal Vision Biotechnology Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
1.86 TWD
Jan 1, 2019
3.27 TWD
Jan 1, 2020
8.10 TWD
Jan 1, 2021
10.26 TWD
Jan 1, 2022
13.16 TWD
Jan 1, 2023
15.79 TWD
Jan 1, 2024
16.55 TWD
Jan 1, 2025
16.25 TWD
The Universal Vision Biotechnology Co EBITDA per Share history
YEAREBITDA per ShareYoY
16.25TWD-1.80%
16.55TWD+4.81%
15.79TWD+20.00%
13.16TWD+28.28%
10.26TWD+26.67%
8.10TWD+147.46%
3.27TWD+76.30%
1.86TWD+9.59%
1.69TWD-33.47%
2.55TWD+23.34%
2.06TWD-6.03%
2.20TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Universal Vision Biotechnology Co Stock analysis

What does Universal Vision Biotechnology Co do? Universal Vision Biotechnology Co., Ltd. generates revenue through the sale of optical instruments, glasses, contact lenses, and glass ornaments. The company also provides laser vision correction equipment and services, trades medical drugs, and offers leasing of medical facilities, clinic operation planning, and medical cosmetology services. Its primary market is Taiwan, where it serves customers seeking vision correction solutions and medical aesthetic treatments. The firm's product portfolio includes optical instruments, glasses, contact lenses, and glass ornaments, alongside medical drug trading. Services such as laser vision correction, medical facility leasing, clinic operation planning, and medical cosmetology are key revenue drivers. Taiwan-based customers, including individuals requiring vision care and clinics needing operational support, form the core market segment. Revenue streams are derived from the direct sale of optical products, medical drug trading, and service-based offerings like laser vision correction and medical cosmetology. The company operates exclusively within Taiwan, focusing on both consumer and clinic-level clients for its comprehensive vision and medical aesthetics solutions. Universal Vision Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Universal Vision Biotechnology Co stock

EBITDA per Share of Universal Vision Biotechnology Co is 16.25 TWD in 2025.

EBITDA per Share of Universal Vision Biotechnology Co changed from 16.55 TWD to 16.25 TWD, representing a -1.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Universal Vision Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Universal Vision Biotechnology Co

All Key Metrics — Universal Vision Biotechnology Co